CRBIOTECH Special Issue: Natural Products and their Applications

Guest editors:

Dr. Devesh Tewari, School of Pharmaceutical Sciences, Lovely Professional University, Punjab, India. Email: [email protected]
Dr. Dongdong Wang, Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, ON, Canada; and The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China. Email: [email protected]

Submission deadline:  1 of September, 2020
Publishing date:  Papers will be published on-line continuously (as soon as accepted)

Natural products are the backbone not only for traditional medical systems, but also for the modern medicine, as many modern drugs are derived from natural sources. Apart from therapeutics, natural products are also broadly utilized in areas like nutrition and food technology, cosmetics and biomaterials development, and in multiple industrial processes.

The special issue of CRBIOTECHNatural Products and their Applications” aims to gather up-to-date knowledge related to the cutting-edge research in the broad scientific area of natural products and their applications. Covered aspects include, but are not limited, to in vitro and in vivo bioactivity and mechanism-of-action studies with natural molecules, biotransformation, biosynthesis, fermentation and secondary metabolite production, metabolic engineering, isolation and characterization of natural compounds, synthesis of natural product derivatives, industrial and commercial applications involving natural products, etc.

The applications and impacts of natural products research are vast and highly relevant scientifically, medically, and economically. Therefore, we are confident that this special issue would be of a great interest for both the broad scientific community as well as for the general public.

Manuscripts should be submitted online at https://www.editorialmanager.com/crbiot/default.aspx. Authors must select the article type, “VSI: Natural Products” while submitting the manuscript in the EM Editorial system. The articles published so far in this special issue can be viewed on the journal website.

Papers will be published on-line continuously (as soon as accepted) and will be listed together on the special issue website. Submission of original research articles, review articles, graphical reviews, as well as short communications is welcome.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except as conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page: https://www.elsevier.com/journals/current-research-in-biotechnology/2590-2628/guide-for-authors. Please visit the page before submitting a manuscript. Please give an indication of “submission to special issue” when submitting your article.

Potential submissions to this Special Issue, including possibility to publish free-of-charge and topic suitability, can be discussed in advance with the guest editors by communication send to the following emails: [email protected] and [email protected]

Brief introduction of CRBIOTECH:

Current Research in Biotechnology (CRBIOTECH) is a new, gold open access journal from Elsevier. The three major pillars leveraged by CRBIOTECH are:

  • Quality(journal paired to the IF = 8.1 Current Opinion in Biotechnology). Submissions acceptance rate: 26%
  • Speed of handling of submitted manuscripts (average time to first decision: 13 days).
  • Visibility (leveraging on open access publishing model, the industry-leading tradition of Elsevier, and superior social media presence).

Featured journal articles can be viewed under the hashtag #CRBIOTECH on different social media networks, including TwitterLinkedInFacebook, and Instagram.

Overview of recent biotech research and its diversity is presented in the journal kick-off manuscript Current research in biotechnology: Exploring the biotech forefront.